Substituted heterocyclic compounds
US11866414B2 · kind B2 · utility
7Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2022 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | May 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.